JP2024533457A5 - - Google Patents

Info

Publication number
JP2024533457A5
JP2024533457A5 JP2024515863A JP2024515863A JP2024533457A5 JP 2024533457 A5 JP2024533457 A5 JP 2024533457A5 JP 2024515863 A JP2024515863 A JP 2024515863A JP 2024515863 A JP2024515863 A JP 2024515863A JP 2024533457 A5 JP2024533457 A5 JP 2024533457A5
Authority
JP
Japan
Prior art keywords
sequence
antigen
multispecific antibody
binding region
isolated multispecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024515863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533457A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/058572 external-priority patent/WO2023037333A1/en
Publication of JP2024533457A publication Critical patent/JP2024533457A/ja
Publication of JP2024533457A5 publication Critical patent/JP2024533457A5/ja
Pending legal-status Critical Current

Links

JP2024515863A 2021-09-13 2022-09-12 がんの治療のためのCD33×Vδ2多重特異性抗体 Pending JP2024533457A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163243493P 2021-09-13 2021-09-13
US63/243,493 2021-09-13
EP21202685 2021-10-14
EP21202685.0 2021-10-14
PCT/IB2022/058572 WO2023037333A1 (en) 2021-09-13 2022-09-12 CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER

Publications (2)

Publication Number Publication Date
JP2024533457A JP2024533457A (ja) 2024-09-12
JP2024533457A5 true JP2024533457A5 (enExample) 2025-09-18

Family

ID=83509005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024515863A Pending JP2024533457A (ja) 2021-09-13 2022-09-12 がんの治療のためのCD33×Vδ2多重特異性抗体

Country Status (8)

Country Link
US (1) US20240409634A1 (enExample)
EP (1) EP4402171A1 (enExample)
JP (1) JP2024533457A (enExample)
KR (1) KR20240055002A (enExample)
AU (1) AU2022344595A1 (enExample)
CA (1) CA3229822A1 (enExample)
TW (1) TW202328193A (enExample)
WO (1) WO2023037333A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501540B2 (en) 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
AR134580A1 (es) 2023-12-08 2026-01-28 Janssen Biotech Inc ANTICUERPOS DE CD33, ANTICUERPOS MULTIESPECÍFICOS DE CD33 / Vd2 Y USOS DE ESTOS
US20260103515A1 (en) 2024-08-08 2026-04-16 Janssen Biotech, Inc. DOSES AND PHARMACEUTICAL COMPOSITIONS OF A CD33 x Vd2 BISPECIFIC ANTIBODY FOR THE TREATMENT OF CANCER

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
AU2010229705A1 (en) 2009-03-27 2011-10-20 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
IN2014CN03887A (enExample) 2011-10-27 2015-10-16 Genmab As
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
US9527927B2 (en) 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
DK2924052T3 (da) 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
PT2970980T (pt) 2013-03-15 2018-11-19 Janssen Biotech Inc Métodos de produção para controlor o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes
US10501540B2 (en) 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
CN109843926B (zh) 2016-09-30 2023-01-20 豪夫迈·罗氏有限公司 针对cd3的双特异性抗体
JOP20190116A1 (ar) * 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
JP7457007B2 (ja) * 2018-09-19 2024-03-27 ラヴァ・セラピューティクス・エヌ・ヴイ 二重作用CD1d免疫グロブリン
EP3792283A1 (en) * 2019-09-16 2021-03-17 Lava Therapeutics B.V. Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
PE20231517A1 (es) * 2020-03-13 2023-09-28 Janssen Biotech Inc Materiales y metodos para la union de siglec-3/cd33

Similar Documents

Publication Publication Date Title
CN115551888B (zh) 抗cd73抗体及其用途
TWI769537B (zh) 標靶bcma的抗體、雙專一性抗體及其用途
CN114181310B (zh) 抗tigit抗体、其药物组合物及用途
KR102068600B1 (ko) Pdl-1 항체, 그 약학적 조성물 및 그 용도
US20220010018A1 (en) MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF
JP2020501531A5 (enExample)
AU2007324509B2 (en) Novel antiproliferation antibodies
WO2020160560A2 (en) Anti-claudin 18 antibodies and methods of use thereof
JP2021510736A5 (enExample)
JP7851303B2 (ja) ヒトcd3イプシロンに結合する新規なヒト抗体
CN116041530A (zh) 多特异性抗体及其制备和使用方法
CN114981301B (zh) Pd1和vegfr2双结合剂
JP2024532489A5 (enExample)
EP4545569A2 (en) Binding protein having h2l2 and hcab structures
IL321280A (en) Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof
AU2019306113B2 (en) Anti-human PD-L1 antibodies and their uses
JP2025516590A5 (enExample)
CN121013865A (zh) 抗cd180结合分子及其用途
JP2024540536A5 (enExample)
US20260022165A1 (en) Antibodies targeting cell surface deposited complement protein c3d and use thereof
HK40066348B (en) Antibody targeting bcma, bispecific antibody, and use thereof
WO2025228406A1 (zh) 结合ly6g6d的分子及其用途
WO2025140548A1 (zh) 一种免疫缀合物及其用途
HK40014714A (en) Anti-gprc5d antibody and molecule containing same
HK1132752B (en) Novel antiproliferation antibodies